Prospective Assessment of Otologic Adverse Events due to Teprotumumab: Preliminary Results.

Emily Kay-RivestIrina BelinskyAnna KozlovaErin ByrdSean O McMenomeyDaniel Jethanamest

Published in: Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery (2023)

In our cohort, a high incidence of otologic symptoms was found to be associated with teprotumumab usage. Subjective hearing decline, changes in ultrahigh-frequency hearing as well as eustachian tube dysfunction may be encountered and suggest the potential ototoxicity of teprotumumab.

Keyphrases

hearing loss
sleep quality
risk factors
human health
risk assessment
depressive symptoms
physical activity
climate change